Trimeris (TRMS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trimeris (TRMS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ben Wa who wrote (97)	9/13/2000 1:39:13 PM
From: Pluvia	of 108

IMO TRMS was run up based on significantly overstated results from their Phase II trial. I see it coming off as the reality sets in that the numbers they have are wrong, and results from future trials very likely get worse as they will have to isolate the role of T-20. Current Phase II T-20 numbers have the benefit of the Genotype selected anti-HIV drugs to make them look better than they likley could be with T-20 alone. Keep in mind Durant showed similar results as the Trimeris phase II T-20 study just using genotype selected anti-HIV drugs... The obvious concern is that much of the positive results shown in the Trimeris T-20 study came from the Genotype selected ant-HIV drugs, not the T-20.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next